UNCY

Unicycive TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

Current thesis

If OLC is approved on the current June 29, 2026 timeline, UNCY moves from a single-asset regulatory story toward a launch-stage nephrology commercial setup with management already describing pre-launch infrastructure, dialysis engagement, and a focused sales plan [#10-K-2026-03-30].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -0.5.

What can break

Commercial uptake is unproven even if approved, with reimbursement, dialysis contracting, and sales-force execution still ahead [#10-K-2026-03-30].

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $7.00 · Bull $15.00 · Bear $3.00

Data freshness

Prices

As of 2026-06-03

Fundamentals

As of 2026-06-02 • Vendor: Data Vendor v1

Scores

As of 2026-06-03 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-03

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $46.50

Why

Momentum79 · Δ7d -0.5

Value41 · Δ7d +0.0

Sentiment55 · Δ7d -2.1

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendImproving

Δ7d

-0.5

Δ21d

-3.5

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendSoftening

Δ7d

-2.1

Δ21d

+19.3

Why this grade

Composite grade B. Momentum 79.5 / Value 41.1 / Sentiment 55.3

Fundamentals (TTM)

As of 2026-06-02

Market Cap

$193.04M

Beta

1.85

Shares Out

21.49M

P/E (TTM) · Derived

-1.6

P/S (TTM)

P/FCF (TTM) · Derived

-4.01

Rev YoY

EPS YoY

+27.7%

Gross Margin

Op Margin

Net Debt

-$26.14M

Current Ratio

3.83

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology